Loading…
Employees: 780
Size Beijing Tong Ren Tang Chinese Medicine (3613.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $617M, the 707th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$5.78 on 6 Nov 2026.
Performance Over six months the shares fell 21.8%, against -21.7% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 20.8% over the last twelve months (peer median +0.3%); the operating margin is 31.6% (peer median 4.6%).
Valuation It trades at 10.9× forward earnings against a peer median of 12.6× (5th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -14% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.7 points above its cost of capital (6.6% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.35B | HK$1.51B | HK$1.61B | HK$1.52B | HK$1.73B |
| Revenue growth | — | -6% | +6% | -12% | — |
| Gross profit | HK$847M | HK$836M | HK$990M | HK$976M | HK$1.09B |
| EBITDA | HK$526M | HK$572M | HK$660M | HK$699M | HK$877M |
| Net income | HK$361M | HK$397M | HK$500M | HK$540M | HK$646M |
| Free cash flow | HK$632M | HK$827M | -HK$201M | HK$502M | HK$519M |
| Capital expenditure | HK$27.4M | HK$41.2M | HK$43.2M | HK$21.9M | HK$38.5M |
| Total debt | n/a | HK$127M | HK$123M | HK$132M | HK$103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3613.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | -7.4% | 2nd highest of 21 |
| 6-month return | -21.8% | -21.7% | 11th highest of 21 |
| Distance from 52-week high | -39.2% | -35.8% | 8th lowest of 21 |
| Revenue growth (TTM) | -20.8% | +0.3% | 3rd lowest of 19 |
| Operating margin | 31.6% | 4.6% | 2nd highest of 19 |
| Forward P/E | 10.9× | 12.6× | 5th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -14.3% | 5.3% | least demanding of 13 |
| Growth delivered (Del g) | +2.8% | +5.8% | 5th lowest of 13 |
| Hurdle (Req g minus delivered) | -17.2 pp | +2.0 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | +8.7 pp | -2.7 pp | 2nd highest of 18 |
| EV / EBITDA | 5.6× | 19.3× | cheapest of 6 |
| Net debt / EBITDA | -4.0× | 1.1× | least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $617M | -22% | -21% | 32% | 10.9× | -14.3% | +2.8% |
| Innova Captab INNOVACAP.NS | India | $618M | +18% | +34% | 12% | 30.4× | 25.4% | +31.4% |
| Chongkundang 185750.KS | South Korea | $611M | -26% | +7% | 4% | 12.6× | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $628M | -21% | -6% | -34% | n/a | n/a | n/a |
| Aclaris Therapeutics ACRS | United States | $604M | -21% | -51% | -1,040% | n/a | n/a | n/a |
| DBV Technologies DBV.PA | France | $633M | -47% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $598M | -23% | -3% | 7% | 9.7× | -3.2% | +4.1% |
| TTY Biopharm 4105.TWO | Taiwan | $596M | +7% | +5% | 33% | 10.9× | -11.1% | +8.8% |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $638M | -12% | -2% | 8% | 7.1× | -4.9% | +6.5% |
| Supriya Lifescience SUPRIYA.NS | India | $593M | -1% | +28% | 30% | 23.6× | 27.9% | +15.8% |
| Olema Pharmaceuticals OLMA | United States | $641M | -51% | n/a | n/a | n/a | n/a | n/a |
| Abbisko Cayman 2256.HK | Hong Kong | $589M | -48% | -83% | -520% | n/a | n/a | n/a |
| Jinhe Biotechnology 002688.SZ | China | $587M | -22% | +9% | 5% | 9.5× | 14.8% | +9.7% |
| Jinling Pharmaceutical 000919.SZ | China | $586M | -14% | -8% | 1% | n/a | 5.0% | +5.0% |
| Oneness Biotech 4743.TWO | Taiwan | $652M | -21% | +37% | -510% | n/a | n/a | n/a |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $653M | -11% | -3% | -1% | n/a | 12.1% | -5.9% |
| GuiZhou SanLi Pharmaceutical 603439.SS | China | $657M | -4% | -6% | 5% | 30.1× | 23.2% | +21.9% |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $661M | -25% | +2% | 4% | n/a | 1.1% | -1.6% |
| Lepu Biopharma 2157.HK | Hong Kong | $663M | -45% | +47% | 7% | 61.2× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $573M | -25% | +32% | 17% | n/a | 5.5% | -1.1% |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $664M | -26% | -10% | -9% | n/a | 0.3% | -17.9% |